24 January 2024
MPP contributed to the third 100 Days Mission Annual Implementation Report that has just been released by the International Pandemic Preparedness Secretariat.
The report assesses international progress towards the 100 Days Mission – a pandemic preparedness initiative established in response to the impact of COVID-19, which aims to work with multisectoral partners to ensure the global availability of diagnostics, therapeutics, and vaccines within the first 100 days of a pandemic threat.
MPP’s contribution to the report was especially key with regards to the development of the therapeutics roadmap, based on MPP’s milestones and challenges during the COVID-19 pandemic and the lessons learned on how we could accelerate equitable access even more. One of the proposed 2024 actions in the 100 DM report calls for “MPP’s pandemic strategy to be supported by the G7, G20 and a broad coalition of companies to standardise the approach to voluntary licence usage during a pandemic” – Source: Annex A, page 92
“The 100 Days Mission is not just about rapidly developing effective medical countermeasures, but it is also about access and equity. This means ensuring that effective therapies become available, from quality-assured sources, at affordable prices and in sufficient volumes to meet demand for the duration of the pandemic and beyond. Voluntary licensing and technology transfer have proven to be effective mechanisms to deliver medical countermeasures to those who need them most in low- and middle-income countries. At the Medicines Patent Pool, we are delighted to have contributed to the development of the Therapeutics Roadmap, based on our experience during COVID-19 and the lessons learned on how we can accelerate equitable access even more. We are equally delighted to be working with partners to accelerate access to future pandemic products through the mRNA Technology Transfer Programme to ensure widely distributed vaccine manufacturing capacity.”
Charles Gore, Executive Director of the Medicines Patent Pool
Click here to download the report to explore these insights: ippsecretariat.org/publications/
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.